Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Moodys
Boehringer Ingelheim
Dow
AstraZeneca

Last Updated: October 1, 2022

Litigation Details for Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited and Camber Pharmaceuticals, Inc. (D. Del. 2021)


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited and Camber Pharmaceuticals, Inc. (D. Del. 2021)

Docket See Plans and Pricing Date Filed 2021-02-10
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand Defendant Referred To
Patents 10,039,745; 10,154,987; 6,977,257; 8,568,747; 8,778,366; 9,000,002; 9,000,011; 9,463,183; 9,616,096; 9,669,008; 9,808,442; 9,855,214; 9,968,553
Link to Docket External link to docket
Small Molecule Drugs cited in Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited and Camber Pharmaceuticals, Inc.
The small molecule drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .
Biologic Drugs cited in Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited and Camber Pharmaceuticals, Inc.
The biologic drug covered by the patents cited in this case is See Plans and Pricing .

Details for Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited and Camber Pharmaceuticals, Inc. (D. Del. 2021)

Date Filed Document No. Description Snippet Link To Document
2022-01-10 89 U.S. patent application Ser. No. 15/802,341, filed Nov. 2, 2017 (now U.S. Pat. No. 10,039,745, issued… U.S. patent application Ser. No. 15/802,341, filed Nov. 2, 2017 (now U.S. Pat. No. 10,039,745, issued…claims of U.S. Patent Nos. 10,772,868 (“the ’868 patent”), and 10,799,476 (“the ’476 patent”) (collectively…The ’868 Patent The ’868 patent is entitled “Enalapril Formulations.” The ’868 patent issued …The ’476 Patent The ’476 patent is entitled “Enalapril Formulations.” The ’476 patent issued on External link to document
2022-01-10 90 Redacted Document disclosed in U.S. Patent Nos. 9,669,008 (the “’008 patent”); 9,808,442; 10,039,745; and 10,154,987,…regarding U.S. Patent Nos. 10,772,868 (the “’868 patent”) and 10,799,476 (the “’476 patent’”) (collectively…476 patents are continuations in the ’008 patent family. The ’008, ’868, and ’476 patents all share… ’476 patent, as well as any patents within this family. 35. The Asserted Patents are directed… 8. ’747 Patent 136. U.S. Patent No. 8,568,747 (the “’747 Patent”) (ANNENAL00005470 External link to document
2022-01-10 92 U.S. Pat. No. 10,039,745, issued Aug. 7, 2018), which is a continuation of U.S. patent application Ser…U.S. patent application Ser. No. 15/802,341, filed Nov. 2, 2017 (now U.S. Pat. No. 10,039,745, issued… OTHER PUBLICATIONS 10,039,745, which is a continuation of application …Rosati, P.C. Nov. 2, 2017, now Pat. No. 10,039,745, which is a continuation of application…dictionary.thefreedictionary.com/hypertension (2008). 10,039,745 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Dow
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.